Pfizer Corporation

Ross James Macrae

Ronald James Ogilvie

Valerie Denise Harding

Michael John Humphrey

Janet Sarah Smith

John Douglas Davis

Elizabeth King

The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941&#x2013;1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37&#xb0; C. Formulations according to the invention are suitable for the treatment of BPH.

Pharmaceutical formulations

The invention provides controlled-release formulations for oral administration containing a cGMP PDE-5 inhibitor. The formulations are useful, inter alia, in the treatment or prevention of sexual dysfunction.

Controlled-release pharmaceutical formulations

A crystalline, &bgr;-polymorphic form of a compound of formula (I):

Salts of an anti-migraine indole derivatives

Salts of an anti-migraine indole derivative

Growing community of inventors

Sandwich, United Kingdom

Ross James Macrae